Photo:
curegt.org
Sep 2, 2026, 06:38
Gene Therapy for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
Glanzmann’s Research Foundation shared a post on LinkedIn:
“We’re revisiting a promising 2025 study that offers a hopeful look at the future of Glanzmann Thrombasthenia gene therapy.
Researchers successfully used gene transfer to increase production of the platelet receptor affected by GT in human cells.
Although this was laboratory research, the findings support the next step: testing the approach in stem cells from people with GT.
We’ve broken down the research and what it could mean for patients and families in an easy-to-understand article.”
Other posts about Glanzmann’s Research Foundation on Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment